What is keratoconus?
Keratoconus, often referred to as “KC,” is an eye condition in which the cornea weakens and thins over time, causing the development of a cone-like bulge and optical irregularity of the cornea. Keratoconus can result in significant visual loss and may lead to corneal transplant in severe cases.
Bring advanced topography into your practice. Glaukos and Topcon have partnered to offer optometrists the advanced technology of Topcon CA-800 topographer at a lower cost of entry.
Watch this video for a quick overview about keratoconus and how it can be treated.
How is progressive keratoconus treated?
Keratoconus can be treated using iLink™—the first and only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help preserve vision.
A new standard of care for progressive keratoconus
iLink™ corneal cross-linking is an innovative therapy that has transformed the treatment of progressive keratoconus. This minimally invasive outpatient procedure uses Photrexa® (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and Photrexa® Viscous riboflavin eye drops, combined with ultraviolet light from the KXL system to1:
- Create new corneal collagen cross-links
- Shorten and thicken collagen fibrils
- Stiffen and strengthen the cornea
[Beshtawi2013/p451/col2/para1/lines10-14; p452/col1/para1/lines3-6; col2/para1/lines10-11; lines23-27]
Did you know?
>95% of the commercially insured population has access to iLink™ corneal cross-linking.
Get the resources you need to help with insurance coverage of iLink™ corneal cross-linking
Find out what signs to look for to identify keratoconus
Explore patient resources about iLink™ corneal cross-linking
1. Beshtawi IM, O’Donnell C, Radhakrishnan H. Biomechanical properties of corneal tissue after ultraviolet-A-riboflavin crosslinking. J Cataract Refract Surg. 2013;39(3):451–462.